Clinical Trial: A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Lewy Body Spectrum Disorders: Investigating Neuropsychiatric Benefit and Adverse Effects in Response to Cholinesterase Inhibitors Using Genetics and Brain SPECT
Brief Summary: Lewy body spectrum disorders are a common group of neurodegenerative diseases that cause memory loss, behavioural and motor disabilities that impair quality of life. Cognitive enhancers help people afflicted with these conditions. However, some people do not benefit from this treatment, while others experience serious side effects. Side effects and poor response lead to hospitalization and early institutionalization. Pharmacogenomics, the study of how DNA variation can influence drug effects, will be combined with functional changes in brain imaging in response to cognitive enhancers in patients with Lewy body disease. The goal is to develop a predictive test that can be administered in the clinic to aid physicians' choice of initial medication. This can reduce health care costs and improve treatment to Canadians suffering from these devastating disorders.
Detailed Summary:
Sponsor: Sunnybrook Health Sciences Centre
Current Primary Outcome:
- Change from baseline in perfusion brain SPECT at 6 months [ Time Frame: 0 and 6 months ]
- Change from baseline in neuropsychological assessment scores at 6 months [ Time Frame: 0 and 6 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Volumetric Brain MRI [ Time Frame: Baseline ]
Original Secondary Outcome: Same as current
Information By: Sunnybrook Health Sciences Centre
Dates:
Date Received: September 10, 2013
Date Started: September 2006
Date Completion:
Last Updated: April 12, 2016
Last Verified: April 2016
